R. Stahel

Discipline

Economies et finances (2)

Type de document

Articles (8) Recensions (5)

Co-auteur

Date

Source

Mot-clé

Lungs--Cancer (7) Treatment (6) Cancer (5) tumeur (4) maladie (4) Chemotherapy (4) Congresses (4) Patients (4) Meetings (4) Human beings (4) Lungs (4) Evidence (4) Chemotherapy (4) Patients (4) maladie (4) thérapie (3) recommandation (3) pathologie (3) papier (3) adulte (3) survie (3) Lugano (3) Complement (3) Specialists (3) Tumors (3) Therapeutics (3) Theater (3) Survival (3) Pathology (3) Paper (3)

Documents écrit par R. Stahel (8) | parle de R. Stahel (0)

PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
S. Peters et al.
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
G. Morgan et al. (2016)
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
W.E. Eberhardt et al. (2015)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
B. Besse et al. (2014)
Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up : 2nd ESMO Consensus Conference on Lung Cancer.
J. Vansteenkiste et al. (2014)
Lung cancer: New evidence - new realities - new challenges
R. Stahel et al. (2012)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
D'Addario G. et al. (2008)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
D.C. Betticher et al. (2006)